Navigation Links
European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
Date:3/6/2008

HENNIGSDORF, Germany, March 6 /PRNewswire/ -- Recently the State of Brandenburg, and the EU, awarded two grants, valued at about 850,000 euro, to Alcat Europe, GmbH, covering marketing and employee costs during early years of operation.

Alcat Europe, a laboratory company located in the BioTech Park in Hennigsdorf (Berlin) engages in testing client blood samples for food and chemical sensitivities through the Alcat test method. The grants demonstrate the confidence the Brandenburg government has in the company's innovative technology, and the company's ability to fulfill the need for a reliable test to identify foods and chemicals associated with numerous health disorders.

"We are pleased that the EU and the State of Brandenburg recognize the importance of food intolerance for the health of the German public," stated Anja Noa Koch, Prokura of Alcat Europe.

Roger Deutsch, CEO of Alcat Europe and the parent US company, CSS, states, "We are grateful for this recognition as well as the substantial resource of highly qualified scientific institutions and personnel in the area to support our growth."

Alcat Europe, GmbH is a wholly owned subsidiary of Cell Science Systems, Ltd., Corp., (CSS) of Deerfield Beach, Florida (USA). CSS, CLIA licensed and registered with the US FDA as a device manufacturer, is a fully integrated medical and health technology company on the cutting edge of research, diagnosis and management of food and chemical sensitivities. CSS operates a lab and manufactures the hardware, software and reagent systems used in the performance of the Alcat test for world wide distribution.

The Alcat test (http://www.alcat.com) has been awarded three international patents. It is an accurate blood test for detecting delayed type reactions to foods, chemicals, and other substances, that manifest inflammatory conditions, such as; migraine, arthritis, skin and respiratory disorders, IBS, and the metabolic syndrome associated with heart disease, diabetes and obesity. A Baylor medical study reported a 98% success amongst its subjects rate in improving weight loss and body composition using the Alcat test. CSS intends to continue to expand its international customer base and build awareness about the health benefits to be derived by following an individually tailored eating plan.


'/>"/>
SOURCE Alcat
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
2. CT Laser Mammography Technology to be Featured at European Congress of Radiology
3. Boston Scientific Announces European Approval of New Heart Failure Lead
4. BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
7. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
8. USC and second sight announce European clinical trial for Argus II retinal implant
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
11. European Commission gives grant to investigate transatlantic oversight of nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/24/2017)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing ... Leader event to highlight new clinical data that will ... the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the Company,s ... in-person and via live webcast on Tuesday, February 28 ... the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 ... dollars, except per share data, unaudited)Three Months Ended December ... BioMarin Revenue $     ... 22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):